GSK
NEWS
CEO Emma Walmsley’s vision includes a projected $46 billion in annual sales from the stand-alone pharma company by 2031 and more than 10% operating profit over the next five years.
GSK CEO Emma Walmsley may face some contentious opposition from key investors interested in forcing a management change following the planned investor update.
Shares of iTeos Therapeutics skyrocketed more than 50% in premarket trading after it struck an agreement with GSM to co-develop and commercialize a cancer treatment.
On June 5, the world marks the 40th anniversary of the HIV epidemic. Biopharma researchers continue to develop safe and effective treatments with an eye to a potential cure.
AbbVie has been the target of multiple legal inquiries and challenges of its pricing and patent protections. Now, a U.S. senator is taking a gander at the company’s taxes.
A two-stage Phase III clinical trial by Sanofi and GSK, is studying a COVID-19 vaccine candidate targeting the original SARS-CoV-2 strain as well as the South African B.1.351 variant.
The EUA was granted base on interim data from the Phase III COMET-ICE trial in high-risk adult outpatients.
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
The company, which isn’t expected to enter the clinic until possibly in 2022, is working to make cell therapies work in solid tumors.
JOBS
IN THE PRESS